Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease

Background: Muscle wasting and decreased muscle oxidative capacity commonly occur in patients with chronic obstructive pulmonary disease (COPD). Polyunsaturated fatty acids (PUFA) have been shown to mediate several inflammatory and metabolic pathways which may be involved in the pathogenesis of muscle impairment in COPD. The aim of this study was to investigate the effect of PUFA modulation on systemic inflammation, reversal of muscle wasting, and functional status in COPD. Methods: Eighty patients with COPD (57 men) with forced expiratory volume in 1 second (FEV1) 37.3 (13.8)% predicted received 9 g PUFA or placebo daily in a double blind randomised fashion during an 8 week rehabilitation programme. Body composition (bioelectrical impedance), functional capacity (lung function, incremental cycle ergometry test, submaximal cycle test, isokinetic quadriceps strength) and inflammatory markers (C-reactive protein (CRP), interleukin (IL)-6 and tumour necrosis factor (TNF)-α) were assessed at baseline and after 8 weeks. Results: Both groups had similar increases in weight, fat-free mass (FFM), and muscle strength. The peak load of the incremental exercise test increased more in the PUFA group than in the placebo group (difference in increase 9.7 W (95% CI 2.5 to 17.0), p = 0.009) even after adjustment for FFM. The duration of the constant work rate test also increased more in patients receiving PUFA (difference in increase 4.3 min (95% CI 0.6 to 7.9), p = 0.023). The positive effects of PUFA could not be attributed to a decrease in systemic levels of CRP, IL-6 and TNF-α. Conclusions: This is the first study to show beneficial effects of PUFA on exercise capacity in patients with COPD.

[1]  J. Elder.  Inhaled corticosteroids: no association with pregnancy induced hypertension in asthmatics , 2005, Thorax.

[2]  M. Beauchesne,et al.  Use of inhaled corticosteroids during pregnancy and risk of pregnancy induced hypertension: nested case-control study , 2005, BMJ : British Medical Journal.

[3]  X. Busquets,et al.  NF-κB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight , 2004, Thorax.

[4]  K. Fearon,et al.  Reduced total energy expenditure and physical activity in cachectic patients with pancreatic cancer can be modulated by an energy and protein dense oral supplement enriched with n-3 fatty acids , 2004, British Journal of Cancer.

[5]  K. Chida,et al.  Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. , 2004, American journal of respiratory and critical care medicine.

[6]  J. Lacour,et al.  Exercise-induced hypoxaemia in master athletes: effects of a polyunsaturated fatty acid diet , 2004, European Journal of Applied Physiology and Occupational Physiology.

[7]  N. Aaronson,et al.  Effect of a protein and energy dense n-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial , 2003, Gut.

[8]  J. Malo,et al.  Controversies in epidemiology of occupational asthma , 2003, European Respiratory Journal.

[9]  E. Wouters,et al.  Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. , 2003, Chest.

[10]  K. Ishihara,et al.  Docosahexaenoic acid suppresses nitric oxide production and inducible nitric oxide synthase expression in interferon-gamma plus lipopolysaccharide-stimulated murine macrophages by inhibiting the oxidative stress. , 2003, Free radical biology & medicine.

[11]  E. Wouters,et al.  Efficacy of nutritional supplementation therapy in depleted patients with chronic obstructive pulmonary disease. , 2003, Nutrition.

[12]  J. Toral,et al.  Comparison of effects of strength and endurance training in patients with chronic obstructive pulmonary disease. , 2002, American journal of respiratory and critical care medicine.

[13]  P. Calder,et al.  The ability of fish oil to suppress tumor necrosis factor alpha production by peripheral blood mononuclear cells in healthy men is associated with polymorphisms in genes that influence tumor necrosis factor alpha production. , 2002, The American journal of clinical nutrition.

[14]  H. van Mameren,et al.  Skeletal muscle fibre-type shifting and metabolic profile in patients with chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[15]  Sally J. Singh,et al.  Bedside methods versus dual energy X‐ray absorptiometry for body composition measurement in COPD , 2002, European Respiratory Journal.

[16]  F. Maltais,et al.  Oxidative enzyme activities of the vastus lateralis muscle and the functional status in patients with COPD , 2000, Thorax.

[17]  E. Wouters,et al.  Characterization of nonresponse to high caloric oral nutritional therapy in depleted patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[18]  E. Wouters,et al.  Exercise-induced lactate increase in relation to muscle substrates in patients with chronic obstructive pulmonary disease. , 2000, American journal of respiratory and critical care medicine.

[19]  K. Fearon,et al.  The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer , 1999, British Journal of Cancer.

[20]  J. Barberà,et al.  Effects of endurance training on skeletal muscle bioenergetics in chronic obstructive pulmonary disease. , 1999, American journal of respiratory and critical care medicine.

[21]  E. Wouters,et al.  Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. , 1997, The European respiratory journal.

[22]  E. Wouters,et al.  Decreased mechanical efficiency in clinically stable patients with COPD. , 1997, Thorax.

[23]  K. Fearon,et al.  Down-regulation of the acute-phase response in patients with pancreatic cancer cachexia receiving oral eicosapentaenoic acid is mediated via suppression of interleukin-6. , 1997, Clinical science.

[24]  J Auwerx,et al.  PPARalpha and PPARgamma activators direct a distinct tissue‐specific transcriptional response via a PPRE in the lipoprotein lipase gene. , 1996, The EMBO journal.

[25]  F. Maltais,et al.  Skeletal muscle adaptation to endurance training in patients with chronic obstructive pulmonary disease. , 1996, American journal of respiratory and critical care medicine.

[26]  J Auwerx,et al.  The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. , 1996, Biochimica et biophysica acta.

[27]  F. Maltais,et al.  Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. , 1996, American journal of respiratory and critical care medicine.

[28]  N. Jones,et al.  Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. , 1995, American journal of respiratory and critical care medicine.

[29]  E. Wouters,et al.  Physiologic effects of nutritional support and anabolic steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. , 1995, American journal of respiratory and critical care medicine.

[30]  L. Jorfeldt,et al.  Long-term oxygen therapy may improve skeletal muscle metabolism in advanced chronic obstructive pulmonary disease patients with chronic hypoxaemia. , 1995, Respiratory medicine.

[31]  D. Moore,et al.  The peroxisome proliferator-activated receptor regulates mitochondrial fatty acid oxidative enzyme gene expression. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Mege,et al.  Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. , 1994, American journal of respiratory and critical care medicine.

[33]  A. Folsom,et al.  Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease. Atherosclerosis Risk in Communities Study Investigators. , 1994, The New England journal of medicine.

[34]  P. Sorlie,et al.  Dietary n-3 polyunsaturated fatty acids and smoking-related chronic obstructive pulmonary disease. Atherosclerosis Risk in Communities Study Investigators. , 1994, The New England journal of medicine.

[35]  A. Mahfoudi,et al.  Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[36]  Standardized lung function testing. Official statement of the European Respiratory Society. , 1993, The European respiratory journal. Supplement.

[37]  M. Gerretsen,et al.  A phase III randomised trial of cisplatinum, methotrextate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Liverpool Head and Neck Oncology Group. , 1990, British Journal of Cancer.

[38]  K. Killian,et al.  Influence of age and stature on exercise capacity during incremental cycle ergometry in men and women. , 1989, The American review of respiratory disease.

[39]  L. F. Black,et al.  Maximal respiratory pressures: normal values and relationship to age and sex. , 2015 .